Despite encouraging results with two- and three-component MUC1 conjugate vaccines in mice models [14–25], immune tolerance to carbohydrate antigens remains a major obstacle in initiating an effective and long-lasting immune protection against malignancies. Here, MUC1 is linked to cancer.